Technology Database
This article was posted on the Diagnostic and Invasive Cardiology website on July 1, 2009

W.L. Gore & Associates Offers GORE VIABAHN Endoprosthesis


The GORE VIABAHN Endoprosthesis is the only stent graft approved by the FDA for the treatment of patients suffering from peripheral arterial disease (PAD) in superficial femoral artery (SFA) lesions and iliac artery lesions.

The GORE VIABAHN Endoprosthesis is constructed with a durable, reinforced, biocompatible, expanded polytetrafluoroethylene (ePTFE) liner attached to an external nitinol stent structure. The outstanding flexibility of the GORE VIABAHN Endoprothesis enables it to traverse tortuous areas of the SFA and conform to the complex anatomy of the artery. The FDA initially approved the device in 2005 for treating PAD in the SFA. Later in 2007, Gore made modifications, which include reducing the profile and adding a heparin bioactive surface. It also made a manufacturing change in 2009, a result of the precision laser trimming technology that enabled the removal of excess material at the device margin, resulting in a contoured edge.

The device is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference diameters ranging from 4 mm to 7.5 mm. The GORE VIABAHN Endoprosthesis is indicated for improving blood flow with symptomatic peripheral arterial disease in the iliac artery lesions with reference vessel diameters from 4 mm to 12 mm.


This article was posted on the Diagnostic and Invasive Cardiology website on July 1, 2009
Subscribe to Diagnostic and Invasive Cardiology
Feedback Welcome... Diagnostic and Invasive Cardiology  welcomes your thoughts/comments.
eMail:daiceditor@sgcmail.com
Mail: Editor, Diagnostic and Invasive Cardiology, Scranton Gillette Communications, Inc., 3030 W. Salt Creek Lane, Suite 201, Arlington Heights, IL 60005-5025